Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Terminated Phase 2Phase 3 Interventional Results available

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

NCT05011513
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
78
States / cities
Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

NCT04754594
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Maternal Immunization
Interventions
BNT162b2, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serological Surveillance for COVID-19 in Central North Carolina

NCT04490174
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
643 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic

NCT04720118
View directory record Official record
Conditions
Parkinson Disease, Covid19, Satisfaction, Patient, Quality of Life
Interventions
No Intervention
Other
Lead sponsor
Towson University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Secutrelvir, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
12 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Coral Gables, Florida • Miami, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

NCT06234462
View directory record Official record
Conditions
Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional

SP16 as a Therapeutic for COVID-19 Induced ARDS

NCT05135624
View directory record Official record
Conditions
SARS CoV 2 Infection, Pneumonia
Interventions
SP16 (6mg), Placebo, SP16 (12 mg)
Drug · Other
Lead sponsor
Serpin Pharma, LLC
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

NCT06928272
View directory record Official record
Conditions
Long COVID
Interventions
Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
Douglas D. Fraser
Other
Eligibility
18 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

NCT04668209
View directory record Official record
Conditions
Coronavirus
Interventions
Silmitasertib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395
View directory record Official record
Conditions
COVID-19
Interventions
CPI-006, Standard of Care
Drug · Other
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
El Centro, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

NCT04551911
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions
Rayaldee, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Withdrawn Phase 1 Interventional

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869
View directory record Official record
Conditions
Acute Lung Injury, ALI, COVID-19
Interventions
RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Not applicable Interventional

Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation

NCT04344561
View directory record Official record
Conditions
COVID, Hypoxic Respiratory Failure
Interventions
Postural Positioning
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protecting Our Community: COVID-19 Testing

NCT04866303
View directory record Official record
Conditions
SARS-CoV-2, Covid19
Interventions
Home-based SARS-CoV-2 test kit
Diagnostic Test
Lead sponsor
Montana State University
Other
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pablo, Montana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

NCT04590586
View directory record Official record
Conditions
COVID-19
Interventions
Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated No phase listed Observational

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04852822
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Duarte, California • Orange, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

NCT04367831
View directory record Official record
Conditions
COVID-19, Venous Thromboses, Arterial Thrombosis
Interventions
Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC, Enoxaparin/Lovenox Intermediate Dose
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predictors of Post-COVID-19 Clinical and Cognitive Consequences

NCT06291870
View directory record Official record
Conditions
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 10:14 PM EDT